Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis

NCT06712654 is registered in ClinicalTrials.gov with R1 Therapeutics as lead sponsor.

NCT NCT06712654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis
Lead sponsor
R1 Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
March 31, 2027
Enrollment
168 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease requiring chronic dialysis, end stage renal disease on dialysis, hyperphosphatemia